» Articles » PMID: 31936812

Associations of Patient Mood, Modulators of Quality of Life, and Pharmaceuticals with Amyotrophic Lateral Sclerosis Survival Duration

Overview
Date 2020 Jan 16
PMID 31936812
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

Associations of modulators of quality of life (QoL) and survival duration are assessed in the fatal motor neuron disease, Amyotrophic Lateral Sclerosis. Major categories include clinical impression of mood (CIM); physical health; patient social support; and usage of interventions, pharmaceuticals, and supplements. Associations were assessed at < 0.05 and < 0.001 significance thresholds using applicable methods (Chi-square, test, ANOVA, logistical regression, random forests, Fisher's exact test) within a retrospective cohort of 1585 patients. Factors significantly correlated with positive (happy or normal) mood included family support and usage of bi-level positive airway pressure (Bi-PAP) and/or cough assist. Decline in physical factors like presence of dysphagia, drooling, general pain, and decrease in ALSFRS-R total score or forced vital capacity (FVC) significantly correlated with negative (depressed or anxious) mood ( < 0.05). Use of antidepressants or pain medications had no association with ALS patient mood ( > 0.05), but were significantly associated with increased survival ( < 0.05). Positive patient mood, Bi-PAP, cough assist, percutaneous endoscopic gastrostomy (PEG), and accompaniment to clinic visits associated with increased survival duration ( < 0.001). Of the 47 most prevalent pharmaceutical and supplement categories, 17 associated with significant survival duration increases ranging +4.5 to +16.5 months. Tricyclic antidepressants, non-opioids, muscle relaxants, and vitamin E had the highest associative increases in survival duration ( < 0.05). Random forests, which examined complex interactions, identified the following pharmaceuticals and supplements as most predictive to survival duration: Vitamin A, multivitamin, PEG supplements, alternative herbs, antihistamines, muscle relaxants, stimulant laxatives, and antispastics. Statins, metformin, and thiazide diuretics had insignificant associations with decreased survival.

Citing Articles

Reasons and experience for patients with amyotrophic lateral sclerosis using traditional Chinese medicine: a CARE-TCM based mixed method study.

Jia Q, Song Y, Zhang C, Li M, Feng L, Sugimoto K BMC Complement Med Ther. 2024; 24(1):231.

PMID: 38867220 PMC: 11167840. DOI: 10.1186/s12906-024-04513-2.


Optimizing breathlessness management in amyotrophic lateral sclerosis: insights from a comprehensive systematic review.

Filipe C, Carreira N, Reis-Pina P BMC Palliat Care. 2024; 23(1):100.

PMID: 38622643 PMC: 11020819. DOI: 10.1186/s12904-024-01429-z.


The value of routine blood work-up in clinical stratification and prognosis of patients with amyotrophic lateral sclerosis.

Gentile F, Maranzano A, Verde F, Bettoni V, Colombo E, Doretti A J Neurol. 2023; 271(2):794-803.

PMID: 37801095 PMC: 10827966. DOI: 10.1007/s00415-023-12015-3.


Enteral tube feeding for amyotrophic lateral sclerosis/motor neuron disease.

Sulistyo A, Abrahao A, Freitas M, Ritsma B, Zinman L Cochrane Database Syst Rev. 2023; 8:CD004030.

PMID: 37579081 PMC: 10413437. DOI: 10.1002/14651858.CD004030.pub4.


Literature-Based Discovery Predicts Antihistamines Are a Promising Repurposed Adjuvant Therapy for Parkinson's Disease.

Tandra G, Yoone A, Mathew R, Wang M, Hales C, Mitchell C Int J Mol Sci. 2023; 24(15).

PMID: 37569714 PMC: 10418861. DOI: 10.3390/ijms241512339.


References
1.
Chio A, Gauthier A, Montuschi A, Calvo A, Di Vito N, Ghiglione P . A cross sectional study on determinants of quality of life in ALS. J Neurol Neurosurg Psychiatry. 2004; 75(11):1597-601. PMC: 1738825. DOI: 10.1136/jnnp.2003.033100. View

2.
Mundt J, Vogel A, Feltner D, Lenderking W . Vocal acoustic biomarkers of depression severity and treatment response. Biol Psychiatry. 2012; 72(7):580-7. PMC: 3409931. DOI: 10.1016/j.biopsych.2012.03.015. View

3.
Kawada T, Thakore N, Pioro E . Depression in ALS in a large self-reporting cohort. Neurology. 2016; 87(15):1631-1632. DOI: 10.1212/01.wnl.0000503501.75283.f1. View

4.
Lou J, Moore D, Gordon P, Miller R . Correlates of quality of life in ALS: Lessons from the minocycline study. Amyotroph Lateral Scler. 2009; 11(1-2):116-21. DOI: 10.3109/17482960902918719. View

5.
Robbins R, Simmons Z, Bremer B, Walsh S, Fischer S . Quality of life in ALS is maintained as physical function declines. Neurology. 2001; 56(4):442-4. DOI: 10.1212/wnl.56.4.442. View